[Form 4] Viemed Healthcare, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Sabrina Heltz, a director of Viemed Healthcare, Inc. (VMD), reported equity awards and changes in beneficial ownership in August 2025. The Form 4 shows grants and vesting events: on 08/19/2025 she was granted 15,029 restricted stock units (RSUs) that vest on 08/19/2026 and 3,757 phantom share units that vest on 08/19/2026. On 08/20/2025 a previously awarded 15,732 RSUs vested and were acquired, and after the reported transactions she beneficially owned 67,491 common shares. Phantom shares pay cash based on the issuer's share price at vesting. The filing was signed by an attorney-in-fact on behalf of the reporting person.

Positive

• Director received equity-based compensation (15,029 RSUs) which aligns incentives with shareholders
• Vested RSUs converted into shares (15,732 acquired on 08/20/2025), increasing reported beneficial ownership to 67,491 common shares

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Director compensation was paid largely in equity and deferred cash units, reflecting routine governance-aligned incentives.

The filing documents director-level compensation delivered as restricted stock units and phantom share units with one tranche vesting immediately (08/20/2025) and other awards vesting on the one-year anniversaries (08/19/2026 and 08/19/2026). Equity-based pay aligns the director's interests with shareholders while phantom units preserve cash flexibility until settlement. The report is a standard Section 16 disclosure of grants and vesting; there are no sales or external-party transfers reported.

Securities Analyst

TL;DR: Transaction is routine insider compensation with limited immediate market impact.

The Form 4 shows acquisition of vested RSUs (15,732 shares) and newly granted awards (15,029 RSUs and 3,757 phantom units). After these events the director beneficially owns 67,491 shares. These are standard non-derivative and derivative compensation instruments; there is no cash sale or disposition reported that would suggest near-term selling pressure. The phantom units convert to cash value at vesting, not shares, which limits immediate share dilution from that component.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heltz Sabrina

(Last) (First) (Middle)

625 E. KALISTE SALOOM RD.

(Street)

LAFAYETTE LA 70508

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/20/2025		M		15,732	A	(1)	67,491	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	08/20/2025		M			15,732	(2)	(2)	Common Shares	15,732	$0	0	D
Restricted Stock Units	(1)	08/19/2025		A		15,029		(3)	08/19/2026	Common Shares	15,029	$0	15,029	D
Phantom Share Units	(4)	08/19/2025		A		3,757		(5)	08/19/2026	Common Shares	3,757	$0	3,757	D

Explanation of Responses:

1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.

2. On August 20, 2024, the reporting person was granted Restricted Stock Units which vest on August 20, 2025.

3. Restricted Stock Units (RSUs) granted to reporting person on August 19, 2025, which vest on the first anniversary of the grant date.

4. Each phantom share represents a right to receive the cash value of one share of the Issuer's common shares which will be determined based on the Issuer's share price on the vesting date.

5. Represents an award granted on August 19, 2025 under the Issuer's Phantom Share Plan which vests on the first anniversary of the grant date.

Remarks:

	/s/ Jesse Bergeron, Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Sabrina Heltz report for VMD?

The Form 4 reports acquisition of 15,732 RSUs on 08/20/2025, grants of 15,029 RSUs and 3,757 phantom units on 08/19/2025, and a beneficial ownership of 67,491 common shares after the transactions.

When do the newly granted RSUs and phantom units vest for VMD director Sabrina Heltz?

The 15,029 RSUs and the 3,757 phantom units granted on 08/19/2025 vest on their first anniversary, 08/19/2026. The 15,732 RSUs referenced vested on 08/20/2025.

Do the phantom share units reported by VMD convert into shares?

No. The filing states each phantom share represents a right to receive the cash value of one common share determined by the issuer's share price on the vesting date.

Did Sabrina Heltz sell any VMD shares in these transactions?

No sales or dispositions are reported. The Form 4 records acquisitions/vestings and new grants only; there are no reported dispositions.

Who signed the Form 4 for Sabrina Heltz?

The Form 4 was signed by Jesse Bergeron, Attorney-in-Fact on 08/20/2025 on behalf of the reporting person.